GlassScriptPhysician profile
Jose A Rodriguez
NPI 1194984781
$5,154.87
in general payments reported to CMS, 2019-2025
29 companies · $832 in 2025
The $832 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $314 · 2021: $482 · 2022: $1,026 · 2023: $931 · 2024: $1,083 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,845.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,111.30 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $942.95 | 2021-2025 | |
| Novo Nordisk INC | $753.91 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $525.74 | 2021-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $381.15 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $200.44 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $164.09 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $125.27 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $124.85 | 2021-2025 | Repatha, Otezla, Repatha |
| Depuy Synthes Sales INC. | $124.72 | 2023 | Viper |
| Inspire Medical Systems, INC. | $122.54 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $78.27 | 2022-2023 | Spravato |
| Genentech USA, INC. | $62.38 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.44 | 2022-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $48.67 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $46.42 | 2021 | |
| Hologic Sales and Service, LLC | $37.05 | 2021-2022 | |
| Redhill Biopharma INC. | $33.17 | 2020 | |
| Horizon Therapeutics Plc | $31.46 | 2019 | |
| Amarin Pharma, INC. | $24.16 | 2022 | |
| Tactile Systems Technology INC | $23.65 | 2023 | Entre Plus, Flexitouch Plus |
| Organon LLC | $20.88 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.44 | 2023 | |
| Astellas Pharma US INC | $19.58 | 2025 | Veozah |
| Duchesnay USA Incorporated | $17.78 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.95 | 2019 | |
| Azurity Pharmaceuticals, INC. | $15.85 | 2023 | Edarbyclor |
| Ibsa Pharma INC. | $11.67 | 2020 | |
| Phadia US INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.